ACU193

DRUG2 trials

Sponsors

Acumen Pharmaceuticals Inc., Acumen Pharmaceuticals

Conditions

Alzheimer DiseaseEarly Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

Phase 1

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

CompletedNCT04931459

Acumen PharmaceuticalsAlzheimer Disease

Start: 2021-06-21End: 2023-06-12Updated: 2023-07-19

Phase 2

A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer’s Disease

RecruitingCTIS2023-509807-34-00

Acumen Pharmaceuticals Inc.Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

Start: 2024-08-12Target: 175Updated: 2026-01-21

Related Papers

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.

2025-02-173 citations

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.

2025-01-014 citations

Intercept‐AD: Development and qualification of a highly sensitive immunoassay to detect total sabirnetug (ACU193) in human CSF

Alzheimer s & Dementia2024-12-01

Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT‐AD Phase 1 Study in Early AD

Alzheimer s & Dementia2024-12-01